SCHEMBL2656554

SCHEMBL2656554

CCOC(=O)Cc1csc(NC(=O)c2cc(OC(C)C)cc(OC(C)C)c2)n1

nearest known ligand 0.78

Predicted protein targets (top 18)

geneUniProtsupporting neighboursconfidence
MAPK1 P28482 2/20 0.72
HTT P42858 2/20 0.72
LMNA P02545 1/20 0.68
TSHR P16473 1/20 0.68
MAPT P10636 5/20 0.64
ALDH1A1 P00352 4/20 0.64
GAA P10253 2/20 0.64
TDP1 Q9NUW8 1/20 0.64
MEN1 O00255 1/20 0.64
KMT2A Q03164 1/20 0.64
NPC1 O15118 1/20 0.60
CYP1A2 P05177 1/20 0.59
CYP3A4 P08684 1/20 0.59
CYP2C9 P11712 1/20 0.59
CYP2C19 P33261 1/20 0.59
SMN1; SMN2 Q16637 2/20 0.59
NPSR1 Q6W5P4 1/20 0.58
PKM P14618 1/20 0.56

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL2660629 0.92 MAPK1 (0.65) MAPK1HTTLMNATSHRMAPT
SCHEMBL2656561 0.88 MAPK1 (0.77) MAPK1HTTLMNATSHRMAPT
SCHEMBL2669485 0.87 GCK (0.53) MAPK1HTTLMNATSHRMAPT
SCHEMBL1263010 0.85 MAPK1 (0.53) MAPK1HTTLMNATSHRMAPT
SCHEMBL2667834 0.83 MAPK1 (0.64) MAPK1HTTLMNATSHRMAPT
SCHEMBL9070827 0.83 MAPK1 (0.63) MAPK1HTTLMNATSHRMAPT
SCHEMBL2668014 0.83 MAPK1 (0.63) MAPK1HTTLMNATSHRMAPT
SCHEMBL2667632 0.82 MAPK1 (0.60) MAPK1HTTLMNATSHRMAPT
SCHEMBL2667758 0.82 MAPK1 (0.63) MAPK1HTTLMNATSHRMAPT
SCHEMBL2655520 0.82 MAPK1 (0.63) MAPK1HTTLMNATSHRMAPT

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 11 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
EP-2019823-B1 BENZAMIDE GLUCOKINASE ACTIVATORS TRANSTECH PHARMA INC (US) 2010-11-24 EP claimed
US-8211925-B2 Benzamide glucokinase activators TRANSTECH PHARMA, INC. (US) 2012-07-03 US disclosed
US-8211925-B2 Benzamide glucokinase activators TRANSTECH PHARMA, INC. (US) 2012-07-03 US disclosed
US-8211925-B2 Benzamide glucokinase activators TRANSTECH PHARMA, INC. (US) 2012-07-03 US disclosed
US-20100331379-A1 BENZAMIDE GLUCOKINASE ACTIVATORS VTVX HOLDINGS I LLC 2010-12-30 US disclosed
US-20100331379-A1 BENZAMIDE GLUCOKINASE ACTIVATORS VTVX HOLDINGS I LLC 2010-12-30 US disclosed
US-20100331379-A1 BENZAMIDE GLUCOKINASE ACTIVATORS VTVX HOLDINGS I LLC 2010-12-30 US disclosed
EP-2019823-B1 BENZAMIDE GLUCOKINASE ACTIVATORS TRANSTECH PHARMA INC (US) 2010-11-24 EP disclosed
EP-2019823-B1 BENZAMIDE GLUCOKINASE ACTIVATORS TRANSTECH PHARMA INC (US) 2010-11-24 EP disclosed
EP-2019823-A2 BENZAMIDE GLUCOKINASE ACTIVATORS Transtech Pharma, Inc. (US) 2009-02-04 EP disclosed
WO-2007125105-A2 BENZAMIDE GLUCOKINASE ACTIVATORS TRANSTECH PHARMA, INC. (US) 2007-11-08 WO disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20100331379-A1 BENZAMIDE GLUCOKINASE ACTIVATORS GCK, GCKR, HK2 MAPK1 2629/4885HTT 810/4885LMNA 3269/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.